Table 2.
Frequencies of Prescribed or Dispensed Lipid‐Lowering Medications by Patient Group
| Group 1 (n=2 224 395) | Group 3 (n=942 902) | Total (N=3 167 297) | |
|---|---|---|---|
| Any lipid‐lowering prescription | 1 134 598 (51.0) | 554 362 (58.8) | 1 688 960 (46.7) |
| Statins | |||
| Lovastatin | 52 402 (2.4) | 12 892 (1.4) | 65 294 (1.8) |
| Simvastatin | 356 943 (16.0) | 122 236 (13.0) | 479 179 (13.2) |
| Atorvastatin | 565 766 (25.4) | 346 529 (36.8) | 9 122 295 (25.1) |
| Pravastatin | 169 738 (7.6) | 74 989 (8.0) | 244 727 (6.7) |
| Rosuvastatin | 74 553 (3.4) | 69 442 (7.4) | 143 995 (4.0) |
| Pitavastatina | 2138 (0.1) | 1990 (0.2) | 4128 (0.1) |
| Fluvastatina | 1034 (0.05) | 594 (0.1) | 1628 (0.04) |
| Nonstatin therapies, n (%) | |||
| Ezetimibea | 25 522 (1.1) | 27 818 (3.0) | 53 340 (1.5) |
| Fenofibric acida | 6611 (0.3) | 4442 (0.5) | 11 053 (0.3) |
| Colesevelama | 4390 (0.2) | 2692 (0.3) | 7082 (0.2) |
| Cholestyramine | 9747 (0.4) | 5268 (0.6) | 15 015 (0.4) |
| Colestipola | 3203 (0.1) | 1578 (0.2) | 4781 (0.1) |
| PCSK9 inhibitors | |||
| Any PCSK9 inhibitor | 362 (0.02) | 1952 (0.21) | 2314 (0.06) |
| Evolocumaba | 222 (0.01) | 1226 (0.13) | 1448 (0.04) |
| Alirocumaba | 140 (0.01) | 726 (0.08) | 866 (0.02) |
Group 1 had dyslipidemia and group 3 had coronary artery disease or coronary heart disease. Data are shown as n (%). Patients may have been prescribed >1 lipid lowering medication during the study (due to switching or adding of medications). All prescriptions per person were captured and are reflected in the table. PCSK9 indicates proprotein convertase subtilisin/kexin type 9.
a
Category contained below‐threshold values (<11 patients) among ≥1 of the participating data marts. Thus, the count in the table is lower than the actual count.